Disposition of 8975 shares by Gillies Hunter of Aerovate Therapeutics at 24.5 subject to Rule 16b-3
AVTE Stock | USD 2.56 0.03 1.19% |
About 54% of Aerovate Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Aerovate Therapeutics suggests that some traders are interested. The current market sentiment, together with Aerovate Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Aerovate Therapeutics stock news signals to limit their universe of possible portfolio assets.
Aerovate |
Filed transaction by Aerovate Therapeutics Officer: Chief Medical Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Aerovate Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Aerovate Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Aerovate Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aerovate Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aerovate Therapeutics Fundamental Analysis
We analyze Aerovate Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerovate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerovate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Aerovate Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Aerovate Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aerovate Therapeutics stock to make a market-neutral strategy. Peer analysis of Aerovate Therapeutics could also be used in its relative valuation, which is a method of valuing Aerovate Therapeutics by comparing valuation metrics with similar companies.
Peers
Aerovate Therapeutics Related Equities
RCUS | Arcus Biosciences | 2.97 | ||||
HOOK | Hookipa Pharma | 0.50 | ||||
CRBU | Caribou Biosciences | 0.56 | ||||
FATE | Fate Therapeutics | 1.19 | ||||
KPTI | Karyopharm Therapeutics | 3.72 | ||||
SANA | Sana Biotechnology | 4.24 | ||||
XFOR | X4 Pharmaceuticals | 5.39 |
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |